Achilles Therapeutics Stock (NASDAQ:ACHL)

Forecast Ownership Financials Chart

Previous Close

$0.99

52W Range

$0.63 - $1.76

50D Avg

$1.02

200D Avg

$0.92

Market Cap

$40.32M

Avg Vol (3M)

$140.63K

Beta

1.34

Div Yield

ACHL Company Profile

Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. It is also developing products for use in the treatment of head and neck squamous cell carcinoma, renal cell carcinoma, triple negative breast cancer, and bladder cancer. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. The company was founded in 2016 and is headquartered in London, the United Kingdom.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Yes

Country

Employees

204

IPO Date

Mar 31, 2021

Website

ACHL Performance

ACHL Financial Summary

	Dec 23	Dec 22	Dec 21
Revenue	-	-	-
Operating Income	$-84.98M	$-78.38M	$-64.19M
Net Income	$-69.94M	$-71.18M	$-61.10M
EBITDA	$-80.25M	$-74.69M	$-60.91M
Basic EPS	$-1.75	$-1.82	$-2.13
Diluted EPS	$-1.75	$-1.82	$-2.13

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison

Ticker	Company
SPRO	Spero Therapeutics, Inc.
NUVB	Nuvation Bio Inc.
NXTC	NextCure, Inc.
CTMX	CytomX Therapeutics, Inc.
ASMB	Assembly Biosciences, Inc.
TIL	Instil Bio, Inc.